Can a Ring on Your Finger Really Tell How Well You Slept? Oura Faces a Lawsuit Over That Question

A proposed class action lawsuit filed against Oura on August 20, 2026, in San Francisco accuses the smart ring maker of misleading consumers about how accurate its sleep tracking really is. The complaint, Surber v. Oura Inc. et al. (case number 26-cv-08686), was filed by Clarkson Law Firm. It alleges that Oura rings cannot actually measure the signals needed to assess sleep quality or determine sleep stages, and instead rely on AI-generated estimates (TechCrunch).

The core argument is that sleep happens in the brain, and a ring on your finger cannot detect brain activity. The complaint states that "sleep happens in the brain, not on one's finger." Sleep researchers have said something similar publicly: that devices like the Oura ring do not directly measure sleep, and users should think about how much they trust the results (AP News).

The lawsuit focuses on Oura's marketing. The complaint alleges the company marketed its ring as "built for accuracy" and offering "unparalleled accuracy." It also says Oura claimed 79% accuracy in its measurements and later said it achieved 95% sleep-staging accuracy compared with clinical sleep labs. According to the complaint, the real performance is far worse: Oura's sleep estimates allegedly have "a coin flip's chance of being correct."

Oura rings are priced at $300 and up, according to the complaint, which argues that consumers bought the rings based on those specific accuracy claims. The suit seeks to stop Oura from falsely advertising its products and to get restitution for people who purchased rings based on the allegedly false claims.

Ryan Clarkson, co-founder and managing partner at Clarkson Law Firm, said misinformation cannot be tolerated when people rely on a device to make decisions about their health. Oura did not respond to TechCrunch's request for comment.

The complaint points to a history of user frustration. Oura users have posted complaints online for years about the ring's sleep accuracy. Some said they felt they slept poorly but the device told them their sleep was excellent. These stories predate the lawsuit but support its main argument: that the gap between what Oura promises and what the ring actually does is not an occasional error but a built-in limitation of the device itself.

This is not the only legal trouble for Oura. The company faces three lawsuits from former promoters who say they agreed to promote the ring in exchange for stock options worth millions of dollars that Oura never paid (Reuters). Oura also filed confidentially for a US initial public offering (IPO) in May 2026 (Bloomberg). The IPO filing means the accuracy lawsuit, the promoter disputes, and any regulatory attention to health claims will likely affect the company's pre-IPO risk disclosures and valuation.

The technical question at the heart of the case is one the wearables industry has dealt with since fitness bands first added sleep tracking. In a clinical sleep study, technicians use a method called polysomnography, which involves placing sensors on the head to monitor brain waves, eye movement, and muscle activity to identify sleep stages. Consumer wearables like the Oura ring take a different approach: they use small light sensors on the skin to track heart rate, body temperature, and movement, and from that data they infer, or guess, what sleep stage you are in. The complaint's argument is that this process is essentially an AI-generated estimate, not an actual measurement of sleep.

What gives the lawsuit traction is not the science itself, which researchers already understand, but the marketing built on top of it. There is a real difference between a device that gives you a rough sleep score and one sold as having "95% sleep-staging accuracy compared with clinical sleep labs." If the plaintiffs can show that Oura's accuracy claims were not backed by solid scientific studies comparing the ring to clinical sleep tests, that gap between marketing and evidence becomes the basis for legal action.

The broader context here is an industry-wide problem. Every company making a consumer wearable faces the same physical limitation: you cannot fit a brain activity monitor into a ring or a wristband. Fitbit, Apple, Whoop, and Garmin all use similar approaches to estimate sleep stages, and all face questions about accuracy. The distinction the lawsuit is drawing is between estimating sleep and actually measuring it, and between being roughly right and being scientifically validated. If the court agrees that Oura's marketing crossed that line, it could push the entire wearables industry to be more careful with how it describes accuracy, especially when comparing its products to clinical sleep labs.

For now, the complaint is a proposed class action, not a ruling. Oura will have a chance to respond, and the class is not guaranteed to be certified. But the combination of an IPO in progress, existing lawsuits from promoters, and now a consumer accuracy class action puts the company in a difficult spot at a time when investors are watching closely.